| IMRT spares bladder in prostate radiation
BOSTON, Oct. 11 Intensity modulated radiation therapy, or IMRT, spares the bladder more from direct radiation compared to 3-D conformal proton therapy, a U.S. study found.
The Massachusetts General Hospital Department of Radiation Oncology and Harvard Medical School, both in Boston, jointly conducted the study to determine the comparative benefits and drawbacks of IMRT versus 3D-CPT as treatments for patients with prostate cancer and to determine whether specific cases should be assigned to one treatment method over the other.
"This study was important because it reassures a patient with prostate cancer that the methods that are available at his local hospital may, in many cases, be as good as those that are currently only available in a limited number of centers," study author Dr.
Independent MP Bill Casey of Nova Scotia to have surgery for prostate ...
AMHERST, N.S. - A Nova Scotia MP who was kicked out of the federal Conservative caucus for voting against the budget last year is undergoing treatment for prostate cancer. Bill Casey, who sits as an Independent in the House of Commons, is having surgery on Thursday. "The prognosis is that will eliminate the problem," he said Tuesday in an interview. "There may be some other treatments after that just to make sure." He said he expects to be off work for six weeks. Casey, 62, said the cancer was diagnosed during a routine blood test. He said he'd had no symptoms of prostate cancer and was caught by surprise when the tests and biopsies showed he would need the operation. He expects a full recovery and plans to resume his political career by April, including seeking re-election.
Cancer Research UK Invests 10m Pounds In Drug Discovery
Cancer Research UK is investing 10m pounds in drug discovery projects at four universities across the UK.
Project leaders at Imperial College London, University of Oxford, University of Strathclyde and The School of Pharmacy in London will each receive £500k per year for five years to develop anti-cancer drugs.
The grants aim to encourage research into using small molecules to create new and targeted drugs to treat cancer. The projects will range from developing therapies for leukaemia to discovering new drugs to beat drug resistance in breast and prostate cancer treatments.
Professor Herbie Newell, Cancer Research UK's executive director of clinical and translational research, said: "We are in the process of significantly expanding our drug discovery programmes.
|
